How do sensor and meter accuracy standards actually differ for buyers entering the Blood Glucose Monitoring Market?

Meters are held to ISO 15197:2013 tolerance bands at defined concentrations; sensors are judged on MARD, where current products report 8–9%. Demand independent laboratory data rather than sponsor-run comparisons before standardising. [Ref 12] Read More

What contract terms matter most in multi-year sensor supply agreements?

Lock unit pricing to volume tiers with a hard floor and cap annual escalation at CPI. Insist on documented sensor-failure replacement service levels and a firmware-support commitment of at least five years. [Ref 16] Read More

Which reimbursement changes should investors watch most closely in the Blood Glucose Monitoring Market?

Watch coverage decisions for non-insulin Type-2 populations. That single policy category controls the largest untapped patient pool, and any national payer approving it would reset volume forecasts across every supplier. [Ref 4] Read More

How hard is it to integrate continuous sensor data into hospital EHR systems?

Harder than vendors imply. Most platforms expose FHIR-compliant APIs, but reconciling five-minute readings with episodic EHR charting requires middleware and clinical governance on alert thresholds. Budget six to nine months. [Ref 11] Read More

What cybersecurity obligations apply to connected glucose devices?

FDA premarket submissions now require a software bill of materials and a coordinated vulnerability disclosure process. EU MDR adds post-market surveillance duties. Non-compliance blocks clearance outright rather than delaying it. [Ref 5] Read More

Are non-invasive optical sensors a near-term threat to incumbents in the Blood Glucose Monitoring Market?

Not before 2030. No optical or radiofrequency candidate has cleared a regulatory pathway supporting insulin dosing decisions, and wellness-tier launches will not displace reimbursed medical devices. [Ref 12] Read More

Which emerging use cases sit outside conventional diabetes care?

Metabolic-health wearables for non-diabetic consumers, GLP-1 therapy titration support, and perioperative glycaemic protocols in surgical units. Each uses identical hardware with different labelling and reimbursement logic. [Ref 7] Read More

Blood Glucose Monitoring Market (2026 - 2035)

Blood Glucose Monitoring Market Research Report: Size, Share, Trend Analysis By Product Type (Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring Devices, Blood Glucose Test Strips, Lancets), By Technology (Electrochemistry, Optical Method, Transdermal Monitoring), By End Users (Hospitals, Homecare Settings, Ambulatory Surgical Centers), By Applications (Diabetes Management, Obesity Management, Gestational Diabetes Monitoring) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

9.6%

2025 Market Size

USD 27.15 Billion

2035 Market Size

USD 67.90 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/0114-HCR | Pages: 200 | Author: Rahul Gotadki, Nidhi Mandole

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Device |
2. 2.2 By Sector |
3. 2.3 By Region
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2024) |
2. 3.2 Base Year Estimate (2025) |
3. 3.3 Forecast Market Size (2026–2035) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Reimbursement Expansion |
2. 4.2 Structural Prevalence Growth |
3. 4.3 Migration to Home Monitoring |
4. 4.4 Extended Wear Cycles & Cost Per Day
5 Restraints Impact Analysis |
1. 5.1 Consumable Price Deflation |
2. 5.2 Affordability Ceilings in Emerging Economies |
3. 5.3 European Regulatory Friction
6 Opportunity Analysis |
1. 6.1 Type-2 Non-Insulin Population |
2. 6.2 Localised Sensor Manufacturing |
3. 6.3 Glycaemic Data as a Reimbursable Service |
4. 6.4 Hospital Glycaemic Management Contracts |
5. 6.5 Gestational & Pre-Diabetes Screening
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Algorithmic Closed-Loop Adoption |
2. 8.2 Platform & Subscription Economics |
3. 8.3 Non-Invasive Sensing Trajectory |
4. 8.4 Sustainability in Procurement
9 Market Segmentation Analysis |
1. 9.1 By Device | |
  1. 9.1.1 SMBG — Glucometers | |
  2. 9.1.2 SMBG — Test Strips & Consumables | |
  3. 9.1.3 SMBG — Lancets & Accessories | |
  4. 9.1.4 CGM — Sensors | |
  5. 9.1.5 CGM — Transmitters & Receivers | |
  6. 9.1.6 CGM — Integrated Pump Interfaces |
2. 9.2 By End User | |
  1. 9.2.1 Hospitals | |
  2. 9.2.2 Homecare Settings | |
  3. 9.2.3 Diagnostic Centres & Clinics | |
  4. 9.2.4 Others |
3. 9.3 By Patient Type | |
  1. 9.3.1 Type-1 Diabetes | |
  2. 9.3.2 Type-2 Diabetes | |
  3. 9.3.3 Gestational Diabetes |
4. 9.4 By Distribution Channel | |
  1. 9.4.1 Institutional Sales | |
  2. 9.4.2 Retail Pharmacies | |
  3. 9.4.3 Online Pharmacies | |
  4. 9.4.4 Diabetes Clinics
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Abbott Laboratories | |
  2. 10.3.2 Dexcom Inc. | |
  3. 10.3.3 Medtronic plc | |
  4. 10.3.4 Roche Diagnostics | |
  5. 10.3.5 LifeScan Inc. | |
  6. 10.3.6 Ascensia Diabetes Care | |
  7. 10.3.7 ARKRAY Inc. | |
  8. 10.3.8 Ypsomed Holding | |
  9. 10.3.9 Trividia Health | |
  10. 10.3.10 i-SENS Inc. | |
  11. 10.3.11 Senseonics Holdings | |
  12. 10.3.12 Nova Biomedical
11 Recent News & Developments
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Validation |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Blood Glucose Monitoring Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Regional Market Summary, 2025 (USD Billion / Share / CAGR) |
TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Market Size, by Device, 2021–2035 (USD Billion) |
TABLE 12 Global Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 13 Global Market Size, by Patient Type, 2021–2035 (USD Billion) |
TABLE 14 Global Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 15 North America Market Size, by Device, 2021–2035 (USD Billion) |
TABLE 16 Europe Market Size, by Device, 2021–2035 (USD Billion) |
TABLE 17 Asia-Pacific Market Size, by Device, 2021–2035 (USD Billion) |
TABLE 18 Competitive Benchmarking Matrix, 2026 |
TABLE 19 Company Profiles — Key Players |
TABLE 20 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 21 Report Scope & Methodology Summary |
TABLE 22 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics — Drivers, Restraints and Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis — Sensor and Consumable Supply |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend Line, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Curve, 2022–2035 (%) |
FIGURE 6 Device Segment Share, 2025 vs 2035 (%) |
FIGURE 7 End User Segment Share, 2025 (%) |
FIGURE 8 Patient Type Segment Share, 2025 (%) |
FIGURE 9 Distribution Channel Share, 2025 (%) |
FIGURE 10 Regional Revenue Share, 2025 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 Country-Level Contribution Heat Map |
FIGURE 13 Competitive Landscape — Estimated Revenue Share Bands, 2026 |
FIGURE 14 Strategic Positioning Matrix — Scale vs Innovation Intensity

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Device	SMBG (Glucometers, Test Strips & Consumables, Lancets & Accessories); CGM (Sensors, Transmitters & Receivers, Integrated Pump Interfaces)	SMBG — Test Strips & Consumables	CGM — Integrated Pump Interfaces
By End User	Hospitals, Homecare Settings, Diagnostic Centres & Clinics, Others	Homecare Settings	Diagnostic Centres & Clinics
By Patient Type	Type-1 Diabetes, Type-2 Diabetes, Gestational Diabetes	Type-2 Diabetes	Gestational Diabetes
By Distribution Channel	Institutional Sales, Retail Pharmacies, Online Pharmacies, Diabetes Clinics	Retail Pharmacies	Online Pharmacies
By Region	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Device

Sub-Segment	Key Trend
SMBG — Glucometers	Replacement demand shifts toward connected, Bluetooth-enabled units in mid-tier markets
SMBG — Test Strips & Consumables	Volume holds while realised pricing erodes in the mid-single digits annually
SMBG — Lancets & Accessories	Commoditised attach-rate category with limited differentiation
CGM — Sensors	Wear duration extends toward 15 days, cutting annualised cost per patient
CGM — Transmitters & Receivers	Smartphone display substitution suppresses dedicated receiver demand
CGM — Integrated Pump Interfaces	Interoperability certification becomes the competitive moat

Device economics are bifurcating. Consumables deliver cash today under persistent price pressure, while sensors deliver growth at defended pricing — and the crossover point where sensor revenue exceeds consumable revenue lands early in the next decade.

By End User

Sub-Segment	Key Trend
Hospitals	Inpatient sensor clearance opens enterprise-scale glycaemic management contracts
Homecare Settings	Remote monitoring billing codes entrench patient-held device models
Diagnostic Centres & Clinics	Point-of-care screening throughput rises with national NCD programmes
Others	Long-term care and occupational health remain small but steady

Care setting now determines channel economics more than clinical acuity does. Homecare volume flows through pharmacy benefit adjudication with subscription refill behaviour, whereas hospital demand still moves on annual tender cycles.

By Patient Type

Sub-Segment	Key Trend
Type-1 Diabetes	Approaching saturation in reimbursed geographies; competition shifts to algorithm quality
Type-2 Diabetes	The decisive growth question is coverage for non-insulin-treated populations
Gestational Diabetes	Short-duration diagnostic wear creates high-turnover, low-friction demand

Type-1 patients consume the most device value per head; Type-2 patients supply the volume. Any payer that extends sensor coverage to diet- and oral-therapy-managed patients would reprice the entire forecast.

By Distribution Channel

Sub-Segment	Key Trend
Institutional Sales	Centralised procurement compresses unit pricing across China, Brazil and Gulf states
Retail Pharmacies	Pharmacy benefit routing displaces durable medical equipment billing
Online Pharmacies	Subscription refill and direct-to-consumer models scale fastest
Diabetes Clinics	Initiation and titration services anchor early patient capture

Channel choice increasingly decides realised margin. Direct and online routes preserve pricing and capture recurring revenue, while institutional tenders trade margin for guaranteed volume in high-prevalence emerging economies.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”